Convection-enhanced delivery in the treatment of malignant glioma

Neurological Research

Volumn 28, Issue 5, 2006, Pages 542-548

  Lopez, Kim A ^a   Waziri, Allen E ^a   Canoll, Peter D ^a   Bruce, Jeffrey N ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Chemotherapy; Convection enhanced delivery; Glioma

Indexed keywords

4 BORONOPHENYLALANINE; ANTINEOPLASTIC AGENT; APRIL PROTEIN; BLEOMYCIN; BORON DERIVATIVE; CARBOPLATIN; CARMUSTINE; CETUXIMAB; CHIMERIC ANTIBODY; CISPLATIN; COTARA; CYTOTOXIN; DIPHTHERIA TOXIN; DNA; GANCICLOVIR; GEMCITABINE; IMMUNOTOXIN; INTERLEUKIN 13; INTERLEUKIN 4; O (2 FLUOROETHYL)TYROSINE F 18; PACLITAXEL; PSEUDOMONAS EXOTOXIN; RADIOPHARMACEUTICAL AGENT; STATIN; TEMOZOLOMIDE; THYMIDINE KINASE; TOPOTECAN; TP 38; TRANSFERRIN; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 1;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; AMNESIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATAXIC APHASIA; CANCER CHEMOTHERAPY; CANNULA; CLINICAL TRIAL; COMMUNICATING HYDROCEPHALUS; CONFUSION; CONVECTION ENHANCED DELIVERY; CONVULSION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; EDEMA; EXTRACELLULAR SPACE; FACIAL NERVE PARALYSIS; FATIGUE; FEVER; GENE THERAPY; GLIOBLASTOMA; HEADACHE; HEMIANOPIA; HEMIPARESIS; HUMAN; INFUSION RATE; INTERSTITIUM; INTRACRANIAL HYPERTENSION; LACTATE DEHYDROGENASE BLOOD LEVEL; LETHARGY; LEUKOCYTOSIS; LIVER DYSFUNCTION; MENINGITIS; MORPHOLOGY; NAUSEA; NEUROLOGIC DISEASE; NEUTRON CAPTURE THERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; REVIEW; SEIZURE; SIMPLE PARTIAL SEIZURE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPEECH DISORDER; SURVIVAL RATE; TUMOR NECROSIS; TUMOR RECURRENCE; WEAKNESS;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; GLIOMA; HUMANS; RATS;

EID: 33746488235     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164106X116836     Document Type: Review

References (42)

1. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol (Berl) 2005; 109: 93-108
2. Central Brain Tumor Registry of the United States. Available at: http://www.cbtrus.org/2004-2005/tables/2005.table19.pdf accessed 15 October 2005
3. Barker FG 2nd, Chang SM, Gutin PH, et al. Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 1998; 42: 709-720
4. Bobo RH, Laske DW, Akbasak A, et al. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 1994; 91: 2076-2080
5. Broaddus WC, Prabhu SS, Gillies GT, et al. Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion. J Neurosurg 1998; 88: 734-742
6. Groothuis DR, Benalcazar H, Allen CV, et al. Comparison of cytosine arabinoside delivery to rat brain by intravenous, intrathecal, intraventricularand intraparenchymal routes of administration. Brain Res 2000; 856: 281-290
7. Kaiser MG, Parsa AT, Fine RL, et al. Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model. Neurosurgery 2000; 47: 1391-1398
8. Morrison PF, Chen MY, Chadwick RS, et al. Focal delivery during direct infusion to brain: Role of flow rate, catheter diameter, and tissue mechanics. Am J Physiol 1999; 277: R1218-R1229
9. Chen MY, Lonser RR, Morrison PF, et al. Variables affecting convection-enhanced delivery to the striatum: A systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J Neurosurg 1999; 90: 315-320
10. Croteau D, Walbridge S, Morrison PF, et al. Real-time in vivo imaging of the convective distribution of a low-molecular-weight tracer. J Neurosurg 2005; 102: 90-97
11. Lonser RR, Gogate N, Morrison PF. Direct convective delivery of macromolecules to the spinal cord. J Neurosurg 1998; 89: 616-622
12. Lonser RR, Walbridge S, Garmestani K, et al. Successful and safe perfusion of the primate brainstem: In vivo magnetic resonance imaging of macromolecular distribution during infusion. J Neurosurg 2002; 97: 905-913
13. Nguyen TT, Pannu YS, Sung C, et al. Convective distribution of macromolecules in the primate brain demonstrated using computerized tomography and magnetic resonance imaging. J Neurosurg 2003; 98: 584-590
14. Sandberg DI, Edgar MA, Souweidane MM. Convection-enhanced delivery into the rat brainstem. J Neurosurg 2002; 96: 885-891
15. Prabhu SS, Broaddus WC, Gillies GT, et al. Distribution of macromolecular dyes in brain using positive pressure infusion: A model for direct controlled delivery of therapeutic agents. Surg Neurol 1998; 50: 367-375
16. Chen MY, Hoffer A, Morrison PF, et al. Surface properties, more than size, limiting convective distribution of virus-sized particles and viruses in the central nervous system. J Neurosurg 2005; 103: 311-319
17. Boucher Y, Salehi H, Witwer B, et al. Interstitial fluid pressure in intracranial tumours in patients and in rodents. Br J Cancer 1997; 75: 829-836
18. 14C-sucrose in RG-2 rat gliomas after intravenous and convection-enhanced delivery. Neuro-oncol 2004; 6: 104-112
19. Vogelbaum MA. Convection enhanced delivery for the treatment of malignant gliomas: Symposium review. J Neurooncol 2005; 73: 57-69
20. Shih AH, Dai C, Hu X, et al. Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res 2004; 64: 4783-4789
21. Uhrbom L, Hesselager G, Nister M, et al. Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res 1998; 58: 5275-5279
22. Burris HA 3rd. Topotecan: Incorporating it into the treatment of solid tumors. Oncologist 1998; 3: 1-3
23. Friedman HS, Kerby T, Fields S, et al. Topotecan treatment of adults with primary malignant glioma: The Brain Tumor Center at Duke. Cancer 1999; 85: 1160-1165
24. Bruce JN, Falavigna A, Johnson JP, et al. Intracerebral clysis in a rat glioma model. Neurosurgery 2000; 46: 683-691
25. Degen JW, Walbridge S, Vortmeyer AO, et al. Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats. J Neurosurg 2003; 99: 893-898
26. Saito R, Bringas JR, Panner A, et al. Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model. Cancer Res 2004; 64: 6858-6862
27. Kawakami K, Kawakami M, Kioi M, et al. Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model. J Neurosurg 2004; 101: 1004-1011
28. Ohlfest JR, Demorest ZL, Motooka Y, et al. Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma. Mol Ther 2005; 12: 778-788
29. Cunningham J, Oiwa Y, Nagy D, et al. Distribution of AAV-TK following intracranial convection-enhanced delivery into rats. Cell Transplant 2000; 9: 585-594
30. Hadaczek P, Mirek H, Berger MS, et al. Limited efficacy of gene transfer in herpes simplex virus-thymidine kinase/ganciclovir gene therapy for brain tumors. J Neurosurg 2005; 102: 328-335
31. Barth RF, Wu G, Yang W, et al. Neutron capture therapy of epidermal growth factor (+) gliomas using boronated cetuximab (IMC-C225) as a delivery agent. Appl Radial Isot 2004; 61: 899-903
32. Yang W, Barth RF, Wu G, et al. Boronated epidermal growth factor as a delivery agent for neutron capture therapy of EGF receptor positive gliomas. Appl Radiat Isot 2004; 61: 981-985
33. Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 1997; 3: 1362-1368
34. Rand RW, Kreitman RJ, Patronas N, et al. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 2000; 6: 2157-2165
35. Weber FW, Floeth F, Asher A, et al. Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir Suppl 2003; 88: 93-103
36. Kunwar S. Convection-enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: Presentation of interim findings from ongoing phase 1 studies. Acta Neurochir Suppl 2003; 88: 105-111
37. Sampson JH, Akabani G, Archer GE, et al. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 2003; 65: 27-35
38. Lidar Z, Mardor Y, Jonas T, et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: A phase I/II clinical study. J Neurosurg 2004; 100: 472-479
39. Pöpperl G, Goldbrunner R, Gildehaus FJ, et al. O-(2-[18F] fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging 2005; 32: 1018-1025
40. Voges J, Reszka R, Gossmann A, et al. Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol 2003; 54: 479-487
41. Patel SJ, Shapiro WR, Laske DW, et al. Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: Initial experience in 51 patients. Neurosurgery 2005; 56: 1243-1252
42. Vogel TW, Bruce JN. Local delivery methods into the CNS. In: Proctor MR, Black PM, eds. Minimally Invasive Neurosurgery, Totowa, NJ, USA: Humana Press, 2005: pp. 297-316